[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:  A Network Meta-analysis].
BACKGROUND
Regimens that combine irinotecan or etoposide with cisplatin or carboplatin have been recommended as first-line regimen for extensive-disease small cell lung cancer (ED-SCLC). In our network meta-analysis, we synthesized the direct and indirect lines of evidence to rank the short-term efficacies of these recommended chemotherapy regimens.


METHODS
We searched databases, including EMBASE, PubMed, CENTRAL and clinicaltrial.gov, for relevant randomized controlled trials (RCTs) that compared the efficacies of these treatments. A risk of bias tool was used to evaluate the quality of the included studies, whereas Stata 13.1 was used for statistical synthesis.


RESULTS
Our study included 10 RCTs that involved 2,378 patients. Compared with that of the regimen that combined etoposide and carboplatin, the complete remission rate was significantly higher in the group treated with irinotecan combined with carboplatin. The efficacy of the regimen that combined irinotecan with carboplatin was significantly superior over that of the combination of etoposide and cisplatin.


CONCLUSIONS
Our data presented here suggest that the effect of Irinotecan combination with Carboplatin is remarkably superior.
Department of Oncology, Tianjin General Hospital,  Tianjin 300052, China.
Yujie
Y
Chen
Department of Orthopedics, Tianjin General Hospital,  Tianjin 300052, China.
Lingxiao
L
Chen
Department of Oncology, Tianjin General Hospital,  Tianjin 300052, China.
Diansheng
D
Zhong
Tianjin Lung Cancer Institute, Tianjin General Hospital,  Tianjin 300052, China.
Jing
J
Wang
Department of Oncology, Tianjin General Hospital,  Tianjin 300052, China.
Lina
L
Peng
Department of Oncology, Tianjin General Hospital,  Tianjin 300052, China.
Xin
X
Feng
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D005047:Etoposide; D000077146:Irinotecan; D016190:Carboplatin; D002945:Cisplatin; D002166:Camptothecin